 We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals. 